Search

Your search keyword '"Vergara, Ander"' showing total 133 results
Start Over Author "Vergara, Ander"
133 results on '"Vergara, Ander"'

5. WCN24-1319 CIRCULATING ACE2 ACTIVITY IS ELEVATED IN SEVERE COVID-19

Author

Martínez-Díaz, Irene, primary, Vergara, Ander, additional, Ortiz, José Tomas, additional, Camara, Antonio Cano, additional, Díaz, Adrià Fernández, additional, Llorens-Cebrià, Carmen, additional, García de Frutos, Pablo, additional, Morales, Albert, additional, Jacobs-Cachá, Conxita, additional, and Soler, Maria José, additional

Published
2024
Full Text
View/download PDF

9. Stimulating cardiac glucose oxidation lessens the severity of heart failure in aged female mice

Author

Sun, Qiuyu, primary, Wagg, Cory S., additional, Güven, Berna, additional, Wei, Kaleigh, additional, de Oliveira, Amanda A., additional, Silver, Heidi, additional, Zhang, Liyan, additional, Vergara, Ander, additional, Chen, Brandon, additional, Wong, Nathan, additional, Wang, Faqi, additional, Dyck, Jason R. B., additional, Oudit, Gavin Y., additional, and Lopaschuk, Gary D., additional

Published
2023
Full Text
View/download PDF

11. Epidemiology of Immune-Mediated Glomerulopathies before and after SARS-CoV-2 Vaccination: A Tertiary Referral Hospital Experience

Author

Zamora, Jorge Iván, primary, López-Martínez, Marina, additional, Patricio Liebana, Marc, additional, Leon Román, Juan Carlos, additional, Bermejo, Sheila, additional, Vergara, Ander, additional, Agraz, Irene, additional, Terrades, Natalia Ramos, additional, Azancot, Maria Antonieta, additional, Toapanta, Nestor, additional, Gabaldon, Maria Alejandra, additional, and Soler, Maria José, additional

Published
2023
Full Text
View/download PDF

12. Endothelin Receptor Antagonists in Kidney Disease

Author

Martínez-Díaz, Irene, primary, Martos, Nerea, additional, Llorens-Cebrià, Carmen, additional, Álvarez, Francisco J., additional, Bedard, Patricia W., additional, Vergara, Ander, additional, Jacobs-Cachá, Conxita, additional, and Soler, Maria José, additional

Published
2023
Full Text
View/download PDF

13. Corrigendum: Enteric Budesonide in Transplant and Native IgA Nephropathy: Real-World Clinical Practice

Author

Lopez-Martinez, Marina, primary, Torres, Irina, additional, Bermejo, Sheila, additional, Moreso, Francesc, additional, Garcia-Carro, Clara, additional, Vergara, Ander, additional, Ramos, Natalia, additional, Perello, Manel, additional, Gabaldon, Alejandra, additional, Azancot, M. Antonieta, additional, Bolufer, Monica, additional, Toapanta, Nestor, additional, Bestard, Oriol, additional, Agraz-Pamplona, Irene, additional, and Soler, Maria Jose, additional

Published
2023
Full Text
View/download PDF

14. Estudio Piloto De Seguimiento En Pacientes Con Enfermedad Renal Diabética Mediante La Aplicación Nora

Author

Toapanta, Néstor, primary, Gavilan, Ester Sánchez, additional, Guirao, Cristina, additional, Román, Juan León, additional, Ramos, Natalia, additional, Vergara, Ander, additional, Azancot, María, additional, Agraz, Irene, additional, Bermejo, Sheila, additional, Montiel, Estefanía, additional, Molina, Carlos, additional, Ribó, Marc, additional, and Soler, María José, additional

Published
2023
Full Text
View/download PDF

15. The membrane-associated protein 17 (MAP17) is up-regulated in response to empagliflozin on top of RAS blockade in experimental diabetic nephropathy

Author

Vergara, Ander, primary, Llorens-Cebrià, Carmen, additional, Martos, Nerea, additional, Martínez-Díaz, Irene, additional, Stein, Frank, additional, Domínguez-Báez, Pamela, additional, Molina-Van den Bosch, Mireia, additional, Rettel, Mandy, additional, Benito, Begoña, additional, Bermejo, Sheila, additional, Pieper, Michael Paul, additional, Jacobs-Cachá, Conxita, additional, and Soler, Maria José, additional

Published
2023
Full Text
View/download PDF

16. Enhanced Cardiorenal Protective Effects of Combining SGLT2 Inhibition, Endothelin Receptor Antagonism and RAS Blockade in Type 2 Diabetic Mice

Author

Vergara, Ander, primary, Jacobs-Cacha, Conxita, additional, Llorens-Cebria, Carmen, additional, Ortiz, Alberto, additional, Martinez-Diaz, Irene, additional, Martos, Nerea, additional, Dominguez-Báez, Pamela, additional, Van den Bosch, Mireia Molina, additional, Bermejo, Sheila, additional, Pieper, Michael Paul, additional, Benito, Begoña, additional, and Soler, Maria Jose, additional

Published
2022
Full Text
View/download PDF

17. Enteric Budesonide in Transplant and Native IgA Nephropathy: Real-World Clinical Practice

Author

Lopez-Martinez, Marina, primary, Torres, Irina, additional, Bermejo, Sheila, additional, Moreso, Francesc, additional, Garcia-Carro, Clara, additional, Vergara, Ander, additional, Ramos, Natalia, additional, Perello, Manel, additional, Gabaldon, Alejandra, additional, Azancot, M. Antonieta, additional, Bolufer, Monica, additional, Toapanta, Nestor, additional, Bestard, Oriol, additional, Agraz-Pamplona, Irene, additional, and Soler, Maria Jose, additional

Published
2022
Full Text
View/download PDF

20. MO154: Enteric Budesonide in IGAN Nephropathy: A Real World Clinical Practice

Author

López Martínez, Marina, primary, Agraz, Irene, additional, Bermejo, Sheila, additional, Moreso, Francesc, additional, Garcia Carro, Clara, additional, Alejandra Gabaldón, M, additional, Vergara, Ander, additional, Ramos Terrada, Natalia, additional, Azancot, María A, additional, Bolufer Cardona, Mónica, additional, Bestard, Oriol, additional, and José Soler Romeo, Maria, additional

Published
2022
Full Text
View/download PDF

22. Urinary angiotensin-converting enzyme 2 and metabolomics in COVID-19-mediated kidney injury.

Author

Vergara, Ander, Wang, Kaiming, Colombo, Daniele, Gheblawi, Mahmoud, Rasmuson, Jaslyn, Mandal, Rupasri, Nonno, Franca Del, Chiu, Brian, Scholey, James W, Soler, María José, Wishart, David S, and Oudit, Gavin Y

Subjects
*SARS-CoV-2, *ANGIOTENSIN converting enzyme, *COVID-19, *ESSENTIAL amino acids, *LIPOCALIN-2
Abstract

Background Angiotensin-converting enzyme 2 (ACE2), the receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is highly expressed in the kidneys. Beyond serving as a crucial endogenous regulator of the renin–angiotensin system, ACE2 also possess a unique function to facilitate amino acid absorption. Our observational study sought to explore the relationship between urine ACE2 (uACE2) and renal outcomes in coronavirus disease 2019 (COVID-19). Methods In a cohort of 104 patients with COVID-19 without acute kidney injury (AKI), 43 patients with COVID-19-mediated AKI and 36 non-COVID-19 controls, we measured uACE2, urine tumour necrosis factor receptors I and II (uTNF-RI and uTNF-RII) and neutrophil gelatinase-associated lipocalin (uNGAL). We also assessed ACE2 staining in autopsy kidney samples and generated a propensity score–matched subgroup of patients to perform a targeted urine metabolomic study to describe the characteristic signature of COVID-19. Results uACE2 is increased in patients with COVID-19 and further increased in those that developed AKI. After adjusting uACE2 levels for age, sex and previous comorbidities, increased uACE2 was independently associated with a >3-fold higher risk of developing AKI [odds ratio 3.05 (95% confidence interval 1.23‒7.58), P  = .017]. Increased uACE2 corresponded to a tubular loss of ACE2 in kidney sections and strongly correlated with uTNF-RI and uTNF-RII. Urine quantitative metabolome analysis revealed an increased excretion of essential amino acids in patients with COVID-19, including leucine, isoleucine, tryptophan and phenylalanine. Additionally, a strong correlation was observed between urine amino acids and uACE2. Conclusions Elevated uACE2 is related to AKI in patients with COVID-19. The loss of tubular ACE2 during SARS-CoV-2 infection demonstrates a potential link between aminoaciduria and proximal tubular injury. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

24. Safety of Obtaining an Extra Biobank Kidney Biopsy Core

Author

Bermejo, Sheila, primary, García-Carro, Clara, additional, Mast, Richard, additional, Vergara, Ander, additional, Agraz, Irene, additional, León, Juan Carlos, additional, Bolufer, Monica, additional, Gabaldon, Maria-Alejandra, additional, Serón, Daniel, additional, Bestard, Oriol, additional, and Soler, Maria Jose, additional

Published
2022
Full Text
View/download PDF

26. Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in human lung tissue cells

Author

Grau-Expósito, Judith, primary, Perea, David, additional, Suppi, Marina, additional, Massana, Núria, additional, Vergara, Ander, additional, Soler, Maria José, additional, Trinite, Benjamin, additional, Blanco, Julià, additional, García-Pérez, Javier, additional, Alcamí, José, additional, Serrano-Mollar, Anna, additional, Rosado, Joel, additional, Falcó, Vicenç, additional, Genescà, Meritxell, additional, and Buzon, Maria J., additional

Published
2022
Full Text
View/download PDF

29. Human lung for the study of SARS-CoV-2

Author

Grau-Expósito, Judith, Perea, David, Suppi, Marina, Massana, Nuria, Vergara, Ander, Soler, María José, Trinité, Benjamin, Blanco, Julià, García-Pérez, Javier, Alcamí, José, Serrano-Mollar, Anna, Rosado, Joel, Falcó, Vicenç, Genesca, Meritxell, Buzón, María José, Generalitat de Catalunya, Instituto de Salud Carlos III, European Commission, Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), Red Española de Investigación en SIDA, Fundació La Marató de TV3, Gilead Sciences, Taller Argal, Buzón, María José, and Buzón, María José [0000-0003-4427-9413]

Abstract

The development of physiological models that reproduce SARS-CoV-2 infection in primary human cells will be instrumental to identify host-pathogen interactions and potential therapeutics. Here, using cell suspensions directly from primary human lung tissues (HLT), we have developed a rapid platform for the identification of viral targets and the expression of viral entry factors, as well as for the screening of viral entry inhibitors and anti-inflammatory compounds. The direct use of HLT cells, without long-term cell culture and in vitro differentiation approaches, preserves main immune and structural cell populations, including the most susceptible cell targets for SARS-CoV-2; alveolar type II (AT-II) cells, while maintaining the expression of proteins involved in viral infection, such as ACE2, TMPRSS2, CD147 and AXL. Further, antiviral testing of 39 drug candidates reveals a highly reproducible method, suitable for different SARS-CoV-2 variants, and provides the identification of new compounds missed by conventional systems, such as VeroE6. Using this method, we also show that interferons do not modulate ACE2 expression, and that stimulation of local inflammatory responses can be modulated by different compounds with antiviral activity. Overall, we present a relevant and rapid method for the study of SARS-CoV-2., This work was primarily supported by a grant from the Health Department of the Government of Catalonia (DGRIS 1_5). This work was additionally supported in part by the Spanish Health Institute Carlos III (ISCIII, PI17/01470; PI19CIII/00004; PI21CIII/00025 and COV20-00679 (MPY 222-20)), the Spanish Secretariat of Science and Innovation and FEDER funds (grant RTI2018-101082-B-I00 [MINECO/FEDER]), the Spanish AIDS network Red Temática Cooperativa de Investigación en SIDA (RD16/0025/0007 and RD16CIII/0002/0001), the European Regional Development Fund (ERDF), the Fundació La Marató TV3 (grants 201805-10FMTV3 and 201814- 10FMTV3), the Gilead fellowships GLD19/00084 and GLD18/00008 and the Becas Taller Argal 2020. M.J.B is supported by the Miguel Servet program funded by the Spanish Health Institute Carlos III (CP17/00179). N.M. is supported by a Ph.D. fellowship from the Vall d’Hebron Institut de Recerca (VHIR). The funders had no role in study design, data collection and analysis, the decision to publish, or preparation of the manuscript.

Published
2021

32. The Impact of Age on Mortality in Chronic Haemodialysis Population with COVID-19

Author

Vergara, Ander, primary, Molina-Van den Bosch, Mireia, additional, Toapanta, Néstor, additional, Villegas, Andrés, additional, Sánchez-Cámara, Luis, additional, Sequera, Patricia, additional, Manrique, Joaquín, additional, Shabaka, Amir, additional, Aragoncillo, Inés, additional, Ruiz, María, additional, Benito, Silvia, additional, Sánchez, Emilio, additional, and Soler, María, additional

Published
2021
Full Text
View/download PDF

35. A Specific Tubular ApoA-I Distribution Is Associated to FSGS Recurrence after Kidney Transplantation

Author

Jacobs-Cachá, Conxita, primary, Puig-Gay, Natàlia, additional, Vergara, Ander, additional, Gabaldon, Maria-Alejandra, additional, Sellarés, Joana, additional, Villena-Ortiz, Yolanda, additional, Agraz, Irene, additional, Moreso, Francesc, additional, Soler, Maria José, additional, Serón, Daniel, additional, and López-Hellín, Joan, additional

Published
2021
Full Text
View/download PDF

36. MO298A SPECIFIC TUBULAR APOA-I DISTRIBUTION IS ASSOCIATED TO FSGS RECURRENCE AFTER KIDNEY TRANSPLANTATION

Author

Jacobs Cachá, Conxita, primary, Puig Gay, Natàlia, additional, Vergara, Ander, additional, Gabaldon, Alejandra, additional, Sellares, Joana, additional, Villena, Yolanda, additional, Agraz, Irene, additional, Seron Micas, Daniel, additional, Moreso, Francesc, additional, Soler, María José, additional, and López Hellín, Joan, additional

Published
2021
Full Text
View/download PDF

38. MO308COULD THE PRESENCE OF ANCAS IN IGA NEPHROPATHY WITH CRESCENTS HAVE A CLINICAL IMPLICATION?

Author

Castañeda Amado, Zaira, primary, Gabaldon, Alejandra, additional, Sanz, María Teresa, additional, Bury, Roxana, additional, Baldallo, Cinthia, additional, Zuñiga, Jose, additional, León, Juan Carlos, additional, Sanchez, Cesar, additional, Vergara, Ander, additional, Bermejo, Sheila, additional, Soler, María José, additional, Seron Micas, Daniel, additional, and Agraz, Irene, additional

Published
2021
Full Text
View/download PDF

39. Evaluation of SARS-CoV-2 Entry, Inflammation and New Therapeutics in Human Lung Tissue Cells

Author

Grau-Expósito, Judith, primary, Perea, David, additional, Suppi, Marina, additional, Massana, Núria, additional, Vergara, Ander, additional, Soler, Maria José, additional, Trinite, Benjamin, additional, Blanco, Julià, additional, García-Pérez, Javier, additional, Alcamí, José, additional, Serrano-Mollar, Anna, additional, Rosado, Joel, additional, Falcó, Vicenç, additional, Genescà, Meritxell, additional, and Buzon, Maria J., additional

Published
2021
Full Text
View/download PDF

42. Matrix Metalloproteinases in Diabetic Kidney Disease

Author

García-Fernández, Nuria, Jacobs-Cachá, Conxita, Mora-Gutiérrez, José María, Vergara, Ander, Orbe, Josune, Soler, María José, and Universitat Autònoma de Barcelona

Subjects
0301 basic medicine, Pathology, medicine.medical_specialty, lcsh:Medicine, Nephron, Review, 030204 cardiovascular system & hematology, Matrix metalloproteinase, Diabetic nephropathy, 03 medical and health sciences, 0302 clinical medicine, Diabetes mellitus, Tissue inhibitors of metalloproteinases, medicine, tissue inhibitors of metalloproteinases, Diabetic kidney disease, Kidney, business.industry, urogenital system, lcsh:R, Glomerulosclerosis, matrix metalloproteinases, General Medicine, medicine.disease, diabetic kidney disease, experimental models of diabetes, 030104 developmental biology, medicine.anatomical_structure, Matrix metalloproteinases, Experimental models of diabetes, Tubulointerstitial fibrosis, business, Kidney disease
Abstract

Around the world diabetic kidney disease (DKD) is the main cause of chronic kidney disease (CKD), which is characterized by mesangial expansion, glomerulosclerosis, tubular atrophy, and interstitial fibrosis. The hallmark of the pathogenesis of DKD is an increased extracellular matrix (ECM) accumulation causing thickening of the glomerular and tubular basement membranes, mesangial expansion, sclerosis, and tubulointerstitial fibrosis. The matrix metalloproteases (MMPs) family are composed of zinc-dependent enzymes involved in the degradation and hydrolysis of ECM components. Several MMPs are expressed in the kidney; nephron compartments, vasculature and connective tissue. Given their important role in DKD, several studies have been performed in patients with DKD proposing that the measurement of their activity in serum or in urine may become in the future markers of early DKD. Studies from diabetic nephropathy experimental models suggest that a balance between MMPs levels and their inhibitors is needed to maintain renal homeostasis. This review focuses in the importance of the MMPs within the kidney and their modifications at the circulation, kidney and urine in patients with DKD. We also cover the most important studies performed in experimental models of diabetes in terms of MMPs levels, renal expression and its down-regulation effect.

Published
2020

43. Challenges in primary focal segmental glomerulosclerosis diagnosis : from the diagnostic algorithm to novel biomarkers

Author

Jacobs-Cachá, Conxita, Vergara, Ander, García-Carro, Clara, Agraz Pamplona, Irene, Toapanta, Néstor, Ariceta Iraola, Gema, Moreso, Francesc, Serón, Daniel, López-Hellín, Joan, Soler, María José, Universitat Autònoma de Barcelona, Institut Català de la Salut, [Jacobs-Cachá C, García-Carro C, Agraz I, Moreso F, Serón D, Soler MJ] Grup de Recerca en Nefrologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Nefrologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Vergara A, Toapanta-Gaibor N] Grup de Recerca en Nefrologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Nefrologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Ariceta G] Red de Investigaciones Renales (RedInRen), Madrid, Spain. Servei de Nefrologia Pediàtrica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [López-Hellín J] Red de Investigaciones Renales (RedInRen), Madrid, Spain. Servei de Bioquímica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Grup de Recerca en Bioquímica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
diagnosis algorithm, 030232 urology & nephrology, Focal segmental glomerulosclerosis, Disease, 030204 cardiovascular system & hematology, Otros calificadores::Otros calificadores::/efectos adversos [Otros calificadores], urologic and male genital diseases, Surgical Procedures, Operative::Surgical Procedures, Operative::Urogenital Surgical Procedures::Urologic Surgical Procedures::Kidney Transplantation [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], 03 medical and health sciences, 0302 clinical medicine, Idiopathic nephrotic syndrome, Glomerulopathy, Ronyons - Malalties - Diagnòstic, Other subheadings::Other subheadings::/adverse effects [Other subheadings], medicine, Minimal change disease, AcademicSubjects/MED00340, Otros calificadores::/terapia [Otros calificadores], Kidney transplantation, CKJ Reviews, focal segmental glomerulosclerosis, Transplantation, Kidney, business.industry, Primary Focal Segmental Glomerulosclerosis, urogenital system, Male Urogenital Diseases::Urologic Diseases::Kidney Diseases [DISEASES], Primary FSGS, biomarkers, Other subheadings::/therapy [Other subheadings], medicine.disease, female genital diseases and pregnancy complications, medicine.anatomical_structure, intervenciones quirúrgicas::trasplante::trasplante de órganos::intervenciones quirúrgicas::trasplante de riñón [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Nephrology, idiopathic nephrotic syndrome, primary FSGS, business, enfermedades urogenitales masculinas::enfermedades urológicas::enfermedades renales [ENFERMEDADES], Nephrotic syndrome, Algorithm, Diagnosis algorithm, Ronyons - Trasplantació - Complicacions, Ronyons - Malalties - Tractament, Biomarkers
Abstract

Biomarcadors; Algoritme de diagnosi; Glomerulosclerosi segmentària focal Biomarcadores; Algoritmo de diagnóstico; Glomeruloesclerosis segmentaria focal Biomarkers; Diagnosis algorithm; Focal segmental glomerulosclerosis Primary or idiopathic focal segmental glomerulosclerosis (FSGS) is a kidney entity that involves the podocytes, leading to heavy proteinuria and in many cases progresses to end-stage renal disease. Idiopathic FSGS has a bad prognosis, as it involves young individuals who, in a considerably high proportion (∼15%), are resistant to corticosteroids and other immunosuppressive treatments as well. Moreover, the disease recurs in 30–50% of patients after kidney transplantation, leading to graft function impairment. It is suspected that this relapsing disease is caused by a circulating factor(s) that would permeabilize the glomerular filtration barrier. However, the exact pathologic mechanism is an unsettled issue. Besides its poor outcome, a major concern of primary FSGS is the complexity to confirm the diagnosis, as it can be confused with other variants or secondary forms of FSGS and also with other glomerular diseases, such as minimal change disease. New efforts to optimize the diagnostic approach are arising to improve knowledge in well-defined primary FSGS cohorts of patients. Follow-up of properly classified primary FSGS patients will allow risk stratification for predicting the response to different treatments. In this review we will focus on the diagnostic algorithm used in idiopathic FSGS both in native kidneys and in disease recurrence after kidney transplantation. We will emphasize those potential confusing factors as well as their detection and prevention. In addition, we will also provide an overview of ongoing studies that recruit large cohorts of glomerulopathy patients (Nephrotic Syndrome Study Network and Cure Glomerulonephropathy, among others) and the experimental studies performed to find novel reliable biomarkers to detect primary FSGS. The authors are current recipients of research grants from the Fondo de Investigación Sanitaria-Feder, Instituto de Salud Carlos III (PI17/00257, PI18/01704 and PI18/01832) and REDinREN (RD16/0009/0030).

Published
2020

44. Sodium-glucose cotransporter 2 inhibition : towards an indication to treat diabetic kidney disease

Author

Górriz, Jose Luis, Navarro-González, Juan F, Ortiz, Alberto, Vergara, Ander, Nuñez, Julio, Jacobs-Cachá, Conxita, Martínez-Castelao, Alberto, Soler, María José, Universitat Autònoma de Barcelona, UAM. Departamento de Medicina, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), and Instituto de Investigación Sanitaria Fundación Jiménez Díaz (ISS-FJD)

Subjects
medicine.medical_specialty, Medicina, 030232 urology & nephrology, Renal function, Reviews, Type 2 diabetes, 030204 cardiovascular system & hematology, Diabetic nephropathy, 03 medical and health sciences, 0302 clinical medicine, Sodium-Glucose Transporter 2, Internal medicine, Diabetes mellitus, Diabetic nephropathies, medicine, Chronic renal failure, Humans, Diabetic Nephropathies, Diabetic kidney disease, ESRD, Sodium-Glucose Transporter 2 Inhibitors, Transplantation, business.industry, Nefropaties diabètiques, medicine.disease, Prognosis, Blood pressure, Diabetes Mellitus, Type 2, Nephrology, Heart failure, Sodium/Glucose Cotransporter 2, Insuficiència renal crònica, business, SGLT2 inhibitors, Kidney disease
Abstract

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have clearly demonstrated their beneficial effect in diabetic kidney disease (DKD) on top of the standard of care [blood glucose control, renin–angiotensin system blockade, smoking cessation and blood pressure (BP) control], even in patients with overt DKD. However, the indication of this drug class is still blood glucose lowering in type 2 diabetic patients with estimated glomerular filtration rate >45mL/min/1.73m2. Based on the new evidence, several scientific societies have emphasized the preferential prescription of SGLT2i for patients at risk of heart failure or kidney disease, but still within the limits set by health authorities. A rapid positioning of both the European Medicines Agency and the US Food and Drug Administration will allow patients with overt DKD to benefit from SGLT2i. Clinical experience suggests that SGLT2i safety management may in part mirror renin–angiotensin blockade safety management in patients with overt DKD. This review focuses on the rationale for an indication of SGTL2i in DKD.We further propose clinical steps for maximizing the safety of SGLT2i in DKD patients on other antidiabetic, BP or diuretic medication, FIS/Fondos FEDER (PI16/02057, PI17/00257, ISCIIIRETIC REDinREN RD016/0009), FRIAT, Sociedad Española de Nefrología, Comunidad de Madrid en Biomedicina B2017/BMD-3686 CIFRA2-CM, and CIBER CV 16/11/00420

Published
2020

48. The New Era for Reno-Cardiovascular Treatment in Type 2 Diabetes

Author

García-Carro, Clara, Vergara, Ander, Agraz Pamplona, Irene, Jacobs-Cachá, Conxita, Espinel, Eugenia, Seron, Daniel, Soler, María José, Universitat Autònoma de Barcelona, Institut Català de la Salut, [García-Carro C, Vergara A] Grup de Recerca en Nefrologia, Vall d’Hebron Institut de Recerca, Barcelona, Spain. Servei de Nefrologia, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. [Agraz I, Jacobs-Cachá C, Espinel E, Seron D, Soler MJ] Grup de Recerca en Nefrologia, Vall d’Hebron Institut de Recerca, Barcelona, Spain. Servei de Nefrologia, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. Red de Investigación Renal (REDINREN), Instituto Carlos III, Madrid, Spain., and Vall d'Hebron Barcelona Hospital Campus

Subjects
Nefropaties diabètiques - Fisiologia patològica, Sodium-glucose co-transporter 2 inhibitors, Otros calificadores::/fisiología [Otros calificadores], Other subheadings::/physiology [Other subheadings], lcsh:Medicine, 030209 endocrinology & metabolism, sodium-glucose co-transporter 2 inhibitors, Type 2 diabetes, Disease, Review, dipeptidyl peptidase 4 inhibitors, 030204 cardiovascular system & hematology, Other subheadings::Other subheadings::/drug therapy [Other subheadings], Bioinformatics, acciones y usos químicos::acciones farmacológicas::acciones y usos químicos::acciones farmacológicas::efectos fisiológicos de los fármacos::hipoglicemiantes::inhibidores de la dipeptidil-peptidasa IV [COMPUESTOS QUÍMICOS Y DROGAS], Glucagon-like peptide-1 receptor agonists, Endocrine System Diseases::Diabetes Mellitus::Diabetes Complications::Diabetic Nephropathies [DISEASES], Chemical Actions and Uses::Pharmacologic Actions::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Hypoglycemic Agents::Dipeptidyl-Peptidase IV Inhibitors [CHEMICALS AND DRUGS], 03 medical and health sciences, 0302 clinical medicine, reno-cardiovascular protection, Diabetes management, Diabetes mellitus, medicine, Nefropaties diabètiques - Tractament, Other subheadings::/therapeutic use [Other subheadings], Diabetic kidney disease, Reno-cardiovascular protection, Dipeptidyl peptidase-4, Otros calificadores::Otros calificadores::/tratamiento farmacológico [Otros calificadores], glucagon-like peptide-1 receptor agonists, diabetes, Otros calificadores::/uso terapéutico [Otros calificadores], business.industry, lcsh:R, Diabetes, General Medicine, medicine.disease, Antidiabètics - Ús terapèutic, diabetic kidney disease, enfermedades del sistema endocrino::diabetes mellitus::complicaciones de la diabetes::nefropatías diabéticas [ENFERMEDADES], Dipeptidyl peptidase 4 inhibitors, Heart failure, Albuminuria, medicine.symptom, business, Kidney disease
Abstract

Diabetes; Diabetic kidney disease; Dipeptidyl peptidase 4 inhibitors Diabetis; Nefropatia diabètica; Inhibidors de la dipeptidil peptidasa 4 Diabetes; Nefropatía diabética; Inhibidores de la dipeptidil peptidasa 4 Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease in the developed world. Until 2016, the only treatment that was clearly demonstrated to delay the DKD was the renin-angiotensin system blockade, either by angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. However, this strategy only partially covered the DKD progression. Thus, new strategies for reno-cardiovascular protection in type 2 diabetic patients are urgently needed. In the last few years, hypoglycaemic drugs, such as sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists, demonstrated a cardioprotective effect, mainly in terms of decreasing hospitalization for heart failure and cardiovascular death in type 2 diabetic patients. In addition, these drugs also demonstrated a clear renoprotective effect by delaying DKD progression and decreasing albuminuria. Another hypoglycaemic drug class, dipeptidyl peptidase 4 inhibitors, has been approved for its use in patients with advanced chronic kidney disease, avoiding, in part, the need for insulinization in this group of DKD patients. Studies in diabetic and non-diabetic experimental models suggest that these drugs may exert their reno-cardiovascular protective effect by glucose and non-glucose dependent mechanisms. This review focuses on newly demonstrated strategies that have shown reno-cardiovascular benefits in type 2 diabetes and that may change diabetes management algorithms. The authors are current recipients of research grants from the FONDO DE INVESTIGACIÓN SANITARIA-FEDER, ISCIII, PI17/00257, and REDINREN, RD16/0009/0030.

Published
2019

50. Challenges in primary focal segmental glomerulosclerosis diagnosis: from the diagnostic algorithm to novel biomarkers.

Author

Jacobs-Cachá, Conxita, Vergara, Ander, García-Carro, Clara, Agraz, Irene, Toapanta-Gaibor, Nestor, Ariceta, Gema, Moreso, Francesc, Serón, Daniel, López-Hellín, Joan, and Soler, Maria José

Subjects
*FOCAL segmental glomerulosclerosis, *DIAGNOSIS, *KIDNEY diseases, *CHRONIC kidney failure, *BIOMARKERS, *KIDNEY transplantation
Abstract

Primary or idiopathic focal segmental glomerulosclerosis (FSGS) is a kidney entity that involves the podocytes, leading to heavy proteinuria and in many cases progresses to end-stage renal disease. Idiopathic FSGS has a bad prognosis, as it involves young individuals who, in a considerably high proportion (∼15%), are resistant to corticosteroids and other immunosuppressive treatments as well. Moreover, the disease recurs in 30–50% of patients after kidney transplantation, leading to graft function impairment. It is suspected that this relapsing disease is caused by a circulating factor(s) that would permeabilize the glomerular filtration barrier. However, the exact pathologic mechanism is an unsettled issue. Besides its poor outcome, a major concern of primary FSGS is the complexity to confirm the diagnosis, as it can be confused with other variants or secondary forms of FSGS and also with other glomerular diseases, such as minimal change disease. New efforts to optimize the diagnostic approach are arising to improve knowledge in well-defined primary FSGS cohorts of patients. Follow-up of properly classified primary FSGS patients will allow risk stratification for predicting the response to different treatments. In this review we will focus on the diagnostic algorithm used in idiopathic FSGS both in native kidneys and in disease recurrence after kidney transplantation. We will emphasize those potential confusing factors as well as their detection and prevention. In addition, we will also provide an overview of ongoing studies that recruit large cohorts of glomerulopathy patients (Nephrotic Syndrome Study Network and Cure Glomerulonephropathy, among others) and the experimental studies performed to find novel reliable biomarkers to detect primary FSGS. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results